2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

628. Aggressive Lymphomas: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5436 Phase I/II trial of acalabrutinib combined with anti-CD19 chimeric antigen receptor T cells (CART) in B-cell lymphoma

Xiancheng Wu, MD, Christina Poh, MD2, Victor Chow, MD3, Ryan C Lynch, MD4, Chaitra Ujjani, MD5, Edus H. Warren, MD, PhD6, Mazyar Shadman, MD, MPH7, Brian G Till, MD8, Vikram Raghunathan, MD9, Jordan Gauthier, MD10, Alexandre V Hirayama, MD11, Stephen Smith, MD12, Taran Gujral, PhD13, Chihiro Morishima, MD14, Qian Wu, PhD15, Jenna Voutsinas, MPH16, Joshua Dizon, BS17, David G Maloney, MD, PhD18, Cameron J. Turtle, MBBS, PhD19, Ajay Gopal, MD20
1 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, United States
3 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
10 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
11 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
12 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
13 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
14 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
15 Fred Hutch Cancer Center, Seattle, United States
16 Fred Hutch Cancer Center, Seattle, United States
17 University of Washington, Seattle, Washington, United States
18 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States
19 Fred Hutch Cancer Center, Seattle, United States, The University of Sydney, Camperdown, New South Wales, Australia
20 Fred Hutch Cancer Center, Seattle, United States, University of Washington, Seattle, Washington, United States

INTRODUCTION

Prior data suggest that bruton tyrosine kinase inhibitors (BTKi) may augment CD19 CART efficacy while reducing toxicities. This is the first prospective trial evaluating BTKi as bridging before, therapy during, and as maintenance after CD19 CART in large B-cell lymphoma (LBCL) and follicular lymphoma (FL).

METHODS

This study completion report describes a phase I/II study of acalabrutinib (acala) with axicabtagene ciloleucel (axi-cel). Patients with R/R LBCL or FL after ≥ 2 prior therapies received acala during 3 phases: 1) bridging (up to 3 weeks prior to leukapheresis through lymphodepletion), 2) cell therapy (CART infusion to day 30), and 3) maintenance (day 30 to 1-year post-CART). The primary endpoint was to describe safety based on rates of grade ≥ 3 CRS and ICANS within 30 days after CART. Secondary endpoints included rates of bridge to CART without additional therapy, objective and complete response rates (ORR and CR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR). Exploratory endpoints included changes in circulating myeloid-derived suppressor cells (MDSC) and cytokines. Changes in cytokines were assessed using paired Wilcoxon signed-rank tests.

RESULTS

Patient characteristics

Between 11/6/20 and 5/30/25, 23 patients enrolled and received acala/axi-cel. Median age and prior therapies were 58 and 3 (range 1-5). Histologies included 12 (52%) DLBCL, 7 (30%) high-grade B-cell lymphoma (HGBCL), 1 (4%) primary mediastinal LBCL (PMBCL), and 3 (13%) FL. Molecular subtypes for DLBCL and HGBCL included 12 (63%) germinal center B-cell-like (GCB), 6 (31%) non-GCB, and 1 unknown. Twenty-two (96%) had stage III/IV disease, and 6 (26%) received prior autologous transplant. Nine (39%) were refractory to and 10 (43%) relapsed within 12 months of last therapy.

Safety

Twenty-one (91%) had CRS (Grade≥3, 4%) and 61% had ICANS (Grade≥3, 35%). Median time to CRS and ICANS onset were both 5 days. Median duration of grade≥3 CRS and ICANS were both 5 days. Two received prophylactic dexamethasone (10 mg daily for 3 days from day of CART), of whom both experienced grade 2 CRS and 1 experienced grade 3 ICANS. Grade≥3 AE occurred in 100% of patients, of which the most common (>10%) included lymphocytopenia (35%) during bridging, and neutropenia (65%), ICANS (35%), thrombocytopenia (22%), and ALT increase (13%) during cell therapy. Eight had drug holds including 4 during maintenance. No patient required dose reduction or stopped acala for toxicity. No patient experienced any grade atrial fibrillation or toxicity-related deaths.

Efficacy

Twenty-two (96%) were successfully bridged to CART with single agent acala, while 1 required additional radiation. One patient lacked evaluable bridging response due to incomplete PET/CT. During bridging, the ORR and CR rates were 25% and 15% in LBCL and no patients with FL responded. Three (50%) non-GCB LBCL, 1 (9%) GCB LBCL, and 1 (14%) HGBCL had an ORR. Four had stable disease. At day 30 post-CART, the ORR and CR rates were 95% and 60% in LBCL, and 100% and 67% in FL patients. During maintenance, 44% who did not achieve a CR at 30 days after CART therapy converted to a CR, including 1 (33%) FL, 1 (14%) HGBCL, 2 (17%) GCB and 1 (17%) non-GCB.

Overall, 96% had an objective response (78% CR, 17% PR). The best ORR and CR rates were 95% and 75% for LBCL, 100% and 83% for non-GCB LBCL, 92% and 67% for GCB LBCL, 86% and 71% for HGBCL, and 100% CR for FL. Median acala duration before CART and on study were 1 and 12 months.

At median follow-up of 40 months (range 3–60), the 24-month PFS, OS, and DOR rates were 64% (95% CI, 47-88%), 72% (55-94%), and 67% (50-91%), respectively. Among patients with LBCL, the 24-month PFS, OS, and DOR rates were 65% (47-90%), 67% (49-93%), and 68% (50%-93%), respectively. At last follow-up, 70% remained alive.

Correlatives

Peripheral MDSC remained stable from baseline to leukapheresis and decreased after CART. MDSC changes did not correlate with response. During bridging, median ferritin decreased from 182 to 178 ng/mL, CRP from 9.9 to 1.2 mg/L, and IL6 from 5 to 3 pg/mL (p=0.058, 0.12, 0.058). Cytokine analyses will be presented.

CONCLUSION

Acalabrutinib monotherapy during bridging was associated with successful receipt of CART. Compared with historical axi-cel data, combination acala may be associated with a lower rate of high-grade CRS, higher response rate, and longer response duration and survival. This strategy warrants further study.

Xiancheng Wu, MD: No relevant conflicts of interest to declare.